Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ATR | Q13535 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 4/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18758369 | 0.83 | CYP4F2 (0.37) | CYP4F2CYP4A11GAAATRLMNA | |
| SCHEMBL8932232 | 0.83 | CYP4F2 (0.44) | CYP4F2CYP4A11GAAATRLMNA | |
| SCHEMBL22604901 | 0.83 | GAA (0.42) | CYP4F2CYP4A11GAAATRLMNA | |
| SCHEMBL22824028 | 0.82 | MEN1 (0.37) | CYP4F2CYP4A11GAAATRLMNA | |
| SCHEMBL14726450 | 0.80 | GAA (0.47) | CYP4F2CYP4A11GAAATRLMNA | |
| SCHEMBL3039870 | 0.80 | CYP4F2 (0.37) | CYP4F2CYP4A11GAAATRLMNA | |
| SCHEMBL3631508 | 0.79 | CYP4F2 (0.34) | CYP4F2CYP4A11GAAATRLMNA | |
| SCHEMBL21024096 | 0.79 | GAA (0.44) | GAALMNAALDH1A1NR3C2TLR8 | |
| SCHEMBL30705522 | 0.78 | NR3C2 (0.36) | CYP4F2CYP4A11GAAATRRXRA | |
| SCHEMBL22449667 | 0.78 | CYP4F2 (0.44) | CYP4F2CYP4A11GAAATRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-11524963-B2 | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2019143991-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-9947482-B2 | Photoelectric conversion element, dye-sensitized solar cell, and metal complex dye used in same | FUJIFILM CORPORATION (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20160042875-A1 | PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, AND METAL COMPLEX DYE USED IN SAME | FUJIFILM CORPORATION (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PDK1, PDPK1, PDK3 | CYP4F2 4667/4885CYP4A11 4197/4885GAA 1210/4885 |
| US-11524963-B2 | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors | RET, ROR1, BRAF | CYP4F2 1933/4885CYP4A11 2395/4885GAA 3222/4885 |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, SLCO1B3, ROR1 | CYP4F2 259/4885CYP4A11 238/4885GAA 1150/4885 |
| US-20160042875-A1 | PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, AND METAL COMPLEX DYE USED IN SAME | CRY1, L1CAM, DLK1 | CYP4F2 3241/4885CYP4A11 2690/4885GAA 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.